<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">17604717</PMID>
      <DateCompleted>
        <Year>2007</Year>
        <Month>08</Month>
        <Day>10</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">0092-8674</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>129</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2007</Year>
              <Month>Jun</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cell</Title>
          <ISOAbbreviation>Cell</ISOAbbreviation>
        </Journal>
        <ArticleTitle>AKT/PKB signaling: navigating downstream.</ArticleTitle>
        <Pagination>
          <StartPage>1261</StartPage>
          <EndPage>1274</EndPage>
          <MedlinePgn>1261-74</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>The serine/threonine kinase Akt, also known as protein kinase B (PKB), is a central node in cell signaling downstream of growth factors, cytokines, and other cellular stimuli. Aberrant loss or gain of Akt activation underlies the pathophysiological properties of a variety of complex diseases, including type-2 diabetes and cancer. Here, we review the molecular properties of Akt and the approaches used to characterize its true cellular targets. In addition, we discuss those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Manning</LastName>
            <ForeName>Brendan D</ForeName>
            <Initials>BD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Genetics and Complex Diseases, Harvard School of Public Health, SPH2-117, Boston, MA 02115, USA. bmanning@hsp.harvard.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cantley</LastName>
            <ForeName>Lewis C</ForeName>
            <Initials>LC</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>CA122617</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA120964</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA122617-02</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 GM041890</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 GM041890</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01-CA089021</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA122617</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01-CA120964</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA120964-01A1</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 CA089021</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>GM41890</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 GM056203</GrantID>
            <Acronym>GM</Acronym>
            <Agency>NIGMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cell</MedlineTA>
        <NlmUniqueID>0413066</NlmUniqueID>
        <ISSNLinking>0092-8674</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D049108" MajorTopicYN="N">Cell Enlargement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018919" MajorTopicYN="N">Neovascularization, Physiologic</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2007</Year>
          <Month>7</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2007</Year>
          <Month>8</Month>
          <Day>11</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2007</Year>
          <Month>7</Month>
          <Day>3</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">17604717</ArticleId>
        <ArticleId IdType="mid">NIHMS121245</ArticleId>
        <ArticleId IdType="pmc">PMC2756685</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cell.2007.06.009</ArticleId>
        <ArticleId IdType="pii">S0092-8674(07)00775-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117:421–426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15137936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, et al.  Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest. 2005;115:2119–2127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1180542</ArticleId>
            <ArticleId IdType="pubmed">16075056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi DR, Andjekovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996a;15:6541–6551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC452479</ArticleId>
            <ArticleId IdType="pubmed">8978681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi DR, Caudwell FB, Andejelkovic M, Hemmings BA, Cohen P. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 1996b;399:333–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8985174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andjelkovic M, Alessi D, Meier R, Fernandez A, Lamb NJC, Frech M, Cron P, Cohen P, Lucocq JM, Hemmings BA. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997;272:31515–31524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9395488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003;63:196–206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12517798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bai L, Wang Y, Fan J, Chen Y, Ji W, Qu A, Xu P, James DE, Xu T. Dissecting multiple steps of GLUT4 trafficking and identifying the sites of insulin action. Cell Metab. 2007;5:47–57.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17189206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991;254:274–277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1833819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005;94:29–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16095999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berwick DC, Hers I, Heesom KJ, Moule SK, Tavare JM. The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes. J Biol Chem. 2002;277:33895–33900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12107176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berwick DC, Dell GC, Welsh GI, Heesom KJ, Hers I, Fletcher LM, Cooke FT, Tavare JM. Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles. J Cell Sci. 2004;117:5985–5993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15546921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;25:917–931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17386267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857–868.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10102273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a) Mol Cell Biol. 2001;21:952–965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC86685</ArticleId>
            <ArticleId IdType="pubmed">11154281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL. Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006;173:279–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2063818</ArticleId>
            <ArticleId IdType="pubmed">16636147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calera MR, Martinez C, Liu H, Jack AK, Birnbaum MJ, Pilch PF. Insulin increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem. 1998;273:7201–7204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9516411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardone MH, Roy N, Stennicke HR, Salvasen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318–1321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9812896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiang GG, Abraham RT. Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem. 2005;280:25485–25490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15899889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins BJ, Deak M, Arthur JS, Armit LJ, Alessi DR. In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation. EMBO J. 2003;22:4202–4211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC175797</ArticleId>
            <ArticleId IdType="pubmed">12912918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature . 1995;378:785–789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8524413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9346240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta SR, Katsov A, Hu L, Petros A, Fesik SW, Yaffe MB, Greenberg ME. 14–3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell. 2000;6:41–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10949026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, Dikkes P, Korsmeyer SJ, Greenberg ME. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell. 2002;3:631–643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12431371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>delPeso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687–689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9381178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998;12:3499–3511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC317244</ArticleId>
            <ArticleId IdType="pubmed">9832503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L, Coffer PJ. FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol. 2002;156:531–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2173339</ArticleId>
            <ArticleId IdType="pubmed">11815629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601–605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10376603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, Pan D. Tsc2 is not a critical target of Akt during normal Drosophila development. Genes Dev. 2004;18:2479–2484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC529535</ArticleId>
            <ArticleId IdType="pubmed">15466161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans. 2007;35:231–235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17371246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell. 2002;13:2276–2288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC117312</ArticleId>
            <ArticleId IdType="pubmed">12134068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eguez L, Lee A, Chavez JA, Miinea CP, Kane S, Lienhard GE, McGraw TE. Full intracellular retention of GLUT4 requires AS160 Rab GTPase activating protein. Cell Metab. 2005;2:263–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16213228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004;64:3892–3899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15172999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16847462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J. 2001;359:1–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1222116</ArticleId>
            <ArticleId IdType="pubmed">11563964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fulton D, Gratton J, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597–601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3637917</ArticleId>
            <ArticleId IdType="pubmed">10376602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001;15:1383–1392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC312704</ArticleId>
            <ArticleId IdType="pubmed">11390358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, et al.  Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM) J Biochem (Tokyo) 2002;277:30958–30967.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12045200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordan JD, Simon MC. Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev. 2007;17:71–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3215290</ArticleId>
            <ArticleId IdType="pubmed">17208433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T, Rangnekar VM. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell. 2005;20:33–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16209943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PK-Calpha, but not S6K1. Dev Cell. 2006;11:859–871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17141160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harthill JE, Pozuelo Rubio M, Milne FC, MacKintosh C. Regulation of the 14–3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells. Biochem J. 2002;368:565–572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1223016</ArticleId>
            <ArticleId IdType="pubmed">12217078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heron-Milhavet L, Franckhauser C, Rana V, Berthenet C, Fisher D, Hemmings BA, Fernandez A, Lamb NJ. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol. 2006;26:8267–8280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1636765</ArticleId>
            <ArticleId IdType="pubmed">16982699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem. 2005;280:26089–26093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15905173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 2004;64:3171–3178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15126356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hutti JE, Jarrell ET, Chang JD, Abbott DW, Storz P, Toker A, Cantley LC, Turk BE. A rapid method for determining protein kinase phosphorylation specificity. Nat Methods. 2004;1:27–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15782149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 2005;171:1023–1034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2171329</ArticleId>
            <ArticleId IdType="pubmed">16365168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16962653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA. 1991;88:4171–4175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC51620</ArticleId>
            <ArticleId IdType="pubmed">1851997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002;22:7831–7841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC134727</ArticleId>
            <ArticleId IdType="pubmed">12391152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katome T, Obata T, Matsushima R, Masuyama N, Cantley LC, Gotoh Y, Kishi K, Shiota H, Ebina Y. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J Biol Chem. 2003;278:28312–28323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12734182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim AH, Khursigara G, Sun X, Franke TF, Chao MV. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 2001;21:893–901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC86680</ArticleId>
            <ArticleId IdType="pubmed">11154276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King FW, Skeen J, Hay N, Shtivelman E. Inhibition of Chk1 by activated PKB/Akt. Cell Cycle. 2004;3:634–637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15107605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3–L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem. 1996;271:31372–31378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8940145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, Roth RA. Identification of a proline-rich Akt substrate as a 14–3-3 binding partner. J Biol Chem. 2003;278:10189–10194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12524439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Monks B, Ge Q, Birnbaum MJ. Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1α transcription coactivator. Nature. 2007 doi: 10.1038/nature05861. in press Published online June 6, 2007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature05861</ArticleId>
            <ArticleId IdType="pubmed">17554339</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8:1153–1160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12244302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 2007;21:1037–1049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1855230</ArticleId>
            <ArticleId IdType="pubmed">17437992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene. 2005;24:7465–7474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594–601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15156201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E–from translation to transformation. Oncogene. 2004;23:3172–3179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15094766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci. 2003;28:573–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14607085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol Cell. 2002;10:151–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci. 1997;22:355–358.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9301337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell. 2006;27:749–760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16543145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA. 2001;98:11598–11603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC58775</ArticleId>
            <ArticleId IdType="pubmed">11504915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McManus EJ, Collins BJ, Ashby PR, Prescott AR, Murray-Tait V, Armit LJ, Arthur JS, Alessi DR. The in vivo role of PtdIns(3,4,5)P(3) binding to PDK1 PH domain defined by knockin mutation. EMBO J. 2004;23:2071–2082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC424399</ArticleId>
            <ArticleId IdType="pubmed">15116068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 2005;24:1571–1583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1142569</ArticleId>
            <ArticleId IdType="pubmed">15791206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 2000;404:782–787.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10783894</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morbidelli L, Donnini S, Ziche M. Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des. 2003;9:521–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12570800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obata T, Yaffe MB, Leparc GG, Piro ET, Maegawa H, Kashiwagi A, Kikkawa R, Cantley L. Use of peptide and protein library screening to define optimal substrate motifs for Akt/PKB. J Biol Chem. 2000;275:108–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10945990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16633338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-κB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10485710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paradis S, Ruvkun G. Caenorhabditis elegans Akt/PKB transduces insulin receptor-like signals from AGE-1 PI3 kinase to the DAF-16 transcription factor. Genes Dev. 1998;12:2488–2498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC317081</ArticleId>
            <ArticleId IdType="pubmed">9716402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005;24:7435–7442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16288290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4:658–665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, et al.  Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005;7:193–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15710331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25:4683–4696.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16892082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10485711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, Moelling K, Yancopoulos GD, Glass DJ. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science. 1999;286:1738–1741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10576741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006;6:729–734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16915295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25:903–915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17386266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem. 2003;278:14599–14602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12637568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, et al.  BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007;401:29–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1698666</ArticleId>
            <ArticleId IdType="pubmed">17040210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA. 1998;95:7772–7777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC22753</ArticleId>
            <ArticleId IdType="pubmed">9636226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekimoto T, Fukumoto M, Yoneda Y. 14–3-3 suppresses the nuclear localization of threonine 157-phosphorylated p27(Kip1) EMBO J. 2004;23:1934–1942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC404318</ArticleId>
            <ArticleId IdType="pubmed">15057270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sekulic A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM, Abraham RT. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 2000;60:3504–3513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10910062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13130303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269:23757–23763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8089148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002;8:1145–1152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12244301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shtivelman E, Sussman J, Stokoe D. A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol. 2002;12:919–924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12062056</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, Nogueira V, Hahn-Windgassen A, Kiyokawa H, Hay N. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 2006;10:269–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17045205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA. 1987;84:5034–5037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC305241</ArticleId>
            <ArticleId IdType="pubmed">3037531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundqvist A, Bengoechea-Alonso MT, Ye X, Lukiyanchuk V, Jin J, Harper JW, Ericsson J. Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF-FBW7. Cell Metab. 2005;1:379–391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16054087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taha C, Liu Z, Jin J, Al-Hasani H, Sonenberg N, Klip A. Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem. 1999;274:33085–33091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10551878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 2001;105:345–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11348591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO’s road. Sci STKE . 2003;2003:RE5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12621150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9:316–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17277771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Viglietto G, Motti ML, Bruni P, Melillo RM, D’Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, et al.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med. 2002;8:1136–1144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12244303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM, Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302:1036–1038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14500851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG., Jr The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005;8:25–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16023596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M, Clurman BE, Roberts JM. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell. 2003;12:381–392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14536078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16469695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaffe MB, Leparc GG, Lai J, Obata T, Volinia S, Cantley LC. A motif-based profile scanning approach for genome-wide prediction of signaling pathways. Nat Biotechnol. 2001;19:348–353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11283593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol. 2002;9:940–944.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12434148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308–318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15048125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell. 2005;20:539–550.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16307918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. EMBO J. 1998;17:5085–5094.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1170836</ArticleId>
            <ArticleId IdType="pubmed">9724644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, Zha X, Tan Y, Hornbeck PV, Mastrangelo AJ, Alessi DR, Polakievicz RD, Comb MJ. Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs. J Biol Chem. 2002;277:39379–39387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12151408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell. 2006;24:185–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1880887</ArticleId>
            <ArticleId IdType="pubmed">17052453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou BP, Liao Y, Xia W, Spohn B, Lee M, Hung M. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol. 2001a;3:245–252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11231573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001b;3:973–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11715018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou GL, Tucker DF, Bae SS, Bhatheja K, Birnbaum MJ, Field J. Opposing roles for Akt1 and Akt2 in Rac/Pak signaling and cell migration. J Biol Chem. 2006;281:36443–36453.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17012749</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B) Science. 1999;286:1741–1744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10576742</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
